188 related articles for article (PubMed ID: 15929806)
1. Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer.
Cartwright T; Lopez T; Vukelja SJ; Encarnacion C; Boehm KA; Asmar L
Clin Colorectal Cancer; 2005 May; 5(1):50-6. PubMed ID: 15929806
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study.
Hofheinz RD; Gnad-Vogt U; Wein A; Saussele S; Kreil S; Pilz L; Hehlmann R; Hochhaus A
Anticancer Drugs; 2005 Jan; 16(1):39-45. PubMed ID: 15613902
[TBL] [Abstract][Full Text] [Related]
3. Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
Cartwright T; Kuefler P; Cohn A; Hyman W; Berger M; Richards D; Vukelja S; Nugent JE; Ruxer RL; Boehm KA; Asmar L
Clin Colorectal Cancer; 2008 Nov; 7(6):390-7. PubMed ID: 19036692
[TBL] [Abstract][Full Text] [Related]
4. The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer.
Shin SJ; Ahn JB; Choi HJ; Cho BC; Jeung HC; Rha SY; Chung HC; Roh JK
Cancer Chemother Pharmacol; 2008 Jan; 61(1):75-81. PubMed ID: 17375304
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients.
Li W; Xu J; Shen L; Liu T; Guo W; Zhang W; Chen Z; Zhu X; Li J
BMC Cancer; 2014 Dec; 14():986. PubMed ID: 25527007
[TBL] [Abstract][Full Text] [Related]
6. First-line treatment with capecitabine combined with irinotecan in patients with advanced colorectal carcinoma: a phase II study.
Assy N; Basher W; Chetver L; Shnaider J; Zidan J
J Clin Gastroenterol; 2012 Apr; 46(4):e27-30. PubMed ID: 22392022
[TBL] [Abstract][Full Text] [Related]
7. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results.
Patt YZ; Lee FC; Liebmann JE; Diamandidis D; Eckhardt SG; Javle M; Justice GR; Keiser W; Salvatore JR; Bexon A; Lin E
Am J Clin Oncol; 2007 Aug; 30(4):350-7. PubMed ID: 17762434
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer.
Bajetta E; Celio L; Ferrario E; Di Bartolomeo M; Denaro A; Dotti K; Mancin M; Bajetta R; Colombo A; Pusceddu S
Ann Oncol; 2007 Nov; 18(11):1810-6. PubMed ID: 17823385
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer.
Renouf DJ; Welch S; Moore MJ; Krzyzanowska MK; Knox J; Feld R; Liu G; MacKay H; Petronis J; Wang L; Chen E
Cancer Chemother Pharmacol; 2012 May; 69(5):1339-44. PubMed ID: 22349811
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer.
Oh SC; Sur HY; Sung HJ; Choi IK; Park SS; Seo JH; Jeen YT; Chun HJ; Shin SW; Mok YJ; Kim JS; Kim YH
Br J Cancer; 2007 May; 96(10):1514-9. PubMed ID: 17473829
[TBL] [Abstract][Full Text] [Related]
13. A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer.
Han JY; Lee DH; Kim HY; Kim EA; Lee JJ; Ju SY; Shin EH; Lee JS
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5909-14. PubMed ID: 14676114
[TBL] [Abstract][Full Text] [Related]
14. Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group.
Garcia-Alfonso P; Muñoz-Martin A; Mendez-Ureña M; Quiben-Pereira R; Gonzalez-Flores E; Perez-Manga G
Br J Cancer; 2009 Oct; 101(7):1039-43. PubMed ID: 19738605
[TBL] [Abstract][Full Text] [Related]
15. Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study.
Tewes M; Schleucher N; Achterrath W; Wilke HJ; Frings S; Seeber S; Harstrick A; Rustum YM; Vanhoefer U
Ann Oncol; 2003 Sep; 14(9):1442-8. PubMed ID: 12954586
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
Kato T; Mishima H; Ikenaga M; Murata K; Ishida H; Fukunaga M; Ota H; Tominaga S; Ohnishi T; Amano M; Ikeda K; Ikeda M; Sekimoto M; Sakamoto J; Monden M
Cancer Chemother Pharmacol; 2008 Feb; 61(2):275-81. PubMed ID: 17429630
[TBL] [Abstract][Full Text] [Related]
17. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.
Rea DW; Nortier JW; Ten Bokkel Huinink WW; Falk S; Richel DJ; Maughan T; Groenewegen G; Smit JM; Steven N; Bakker JM; Semiond D; Kerr DJ; Punt CJ
Ann Oncol; 2005 Jul; 16(7):1123-32. PubMed ID: 15939714
[TBL] [Abstract][Full Text] [Related]
18. Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.
El-Rayes BF; Zalupski MM; Manza SG; Rusin B; Ferris AM; Vaishampayan U; Heilbrun LK; Venkatramanamoorthy R; Shields AF; Philip PA
Cancer Chemother Pharmacol; 2008 Feb; 61(2):283-9. PubMed ID: 17429629
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic or advanced colorectal carcinoma--a dual-centre phase II study: the MAC-6.
Choi CK; Chan RT; Tung SY; Lui L; Siu S; Au GK; Ho JW; Law WL
Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):168-75. PubMed ID: 18155454
[TBL] [Abstract][Full Text] [Related]
20. Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer.
Cassinello J; Alvarez JV; López MJ; Pujol E; Colmenarejo A; Segovia F; Marcos F; Filipovich E; Arcediano A; Castro IG
Clin Colorectal Cancer; 2006 Mar; 5(6):429-35. PubMed ID: 16635282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]